Tutti gli studi
ReclutamentoFASE3INTERVENTISTICO

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

This research study is investigating a new medication, VGA039, for individuals living with Von Willebrand Disease (VWD). VWD is a lifelong bleeding disorder where your blood doesn't clot properly. The study aims to see if giving VGA039 as an injection under the skin can help prevent bleeding episodes. It's a Phase 3 study, which means it's a key step in testing new medicines before they can be made widely available. Researchers want to understand how safe and effective VGA039 is in reducing how often people with all types of VWD experience bleeds. They will compare a period without the new medicine to a period when participants are taking VGA039. Doctors will carefully monitor participants for any side effects and track how well the medicine works to prevent bleeding.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE3
Sponsor
Vega Therapeutics, Inc
Obiettivo di iscrizione
60
Inizio
15 Ott 2025
Completamento stimato
01 Ott 2028

Di cosa tratta questo studio?

This study is about a medical condition called Von Willebrand Disease, often shortened to VWD. VWD is a common bleeding disorder that affects how your blood clots. If you have VWD, your body either doesn't make enough of a protein called von Willebrand factor, or the protein doesn't work as it should. This can lead to longer or heavier bleeding, for example, after an injury, surgery, or during periods.

Researchers are testing a new medication called VGA039. The main goal of this study is to see if VGA039, given as an injection under the skin, can help prevent bleeding episodes in people with VWD. This type of treatment, where you take medication regularly to stop problems before they start, is often called 'prophylaxis'. The study will also carefully check for any side effects of VGA039 and compare it to how you manage your VWD without this specific new medicine.

This is a Phase 3 study, which is a very important stage in developing new medications. It means that VGA039 has already been tested in earlier studies. Now, the researchers need more information from a larger group of people to confirm its safety and effectiveness before it might be considered for wider use. By taking part, you could be helping to find a new way to manage VWD.

Punti chiave

  • This study is testing a new injectable medication (VGA039) for Von Willebrand Disease.
  • It aims to see if VGA039 can prevent bleeding episodes in people with VWD.
  • The study has two main parts: an observation period and a treatment period.
  • It's a Phase 3 study, meaning it's a key step in developing new medicines.
  • You would track your bleeding episodes in a diary throughout the study.
  • Participation could last over a year, with regular health checks.

Chi può essere idoneo?

To join this study, people generally need to be between 12 and 75 years old and have a confirmed diagnosis of any type of Von Willebrand Disease (VWD). You would also need to have experienced a certain number of bleeding episodes in the past year (at least 12, not including heavy periods or bruises under the skin), and your doctor should feel that you would benefit from regular treatment to prevent bleeding.

There are also some reasons why someone might not be able to join. For example, if you are already regularly taking other medications containing von Willebrand factor to prevent bleeding, or if you plan to start such treatments during the study, you probably wouldn't be eligible. The study also cannot include individuals with a history of blood clots or certain serious health conditions affecting organs like your kidneys, heart, or brain. Also, your blood tests for a protein called Factor VIII shouldn't be too high.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you between 12 and 75 years old?
  2. Do you have a confirmed diagnosis of Von Willebrand Disease (any type)?
  3. Have you had at least 12 bleeding episodes in the past year (excluding heavy periods or skin bruises)?
  4. Does your doctor think you could benefit from regular treatment to prevent bleeding?
  5. Do you have any history of blood clots or serious health conditions affecting organs like your heart or kidneys?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, it will involve two main periods. First, there's an 'Observational Period' which lasts at least 24 weeks (about 6 months). During this time, you won't be taking the new study medication, but doctors will collect information about any bleeding episodes you experience and any treatments you use. You'll need to keep a diary to record details about bleeds.

After that, you'll move into the 'Active Treatment Period' which lasts about 49 weeks (around 11-12 months). During this time, you will receive the study medication, VGA039, as an injection under your skin. You'll continue to keep your diary to record any bleeds and what treatments you use. Throughout both periods, the study team will regularly monitor your health, perform blood tests, and check for any side effects. The total duration of your involvement could be over a year.

Rischi e benefici potenziali

Taking part in any medical study has potential benefits and risks. You might benefit from closer monitoring of your VWD and potentially from the new medication if it proves effective in preventing bleeds. However, there's no guarantee the treatment will work for you, and like all medications, VGA039 might have side effects, which the study team will explain in detail. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Località (32)

  • Arkansas Children's Hospital
    Codice postale verificato
    Little Rock, Stati Uniti· Reclutamento
  • Luskin Orthopaedic Institute For Children
    Codice postale verificato
    Los Angeles, Stati Uniti· Reclutamento
  • Stanford University
    Codice postale verificato
    Palo Alto, Stati Uniti· Reclutamento
  • UC Davis Medical Center
    Codice postale verificato
    Sacramento, Stati Uniti· Reclutamento
  • University of California San Francisco
    Codice postale verificato
    San Francisco, Stati Uniti· Reclutamento
  • Yale University School of Medicine
    Codice postale verificato
    New Haven, Stati Uniti· Reclutamento
  • Emory University Hospital
    Codice postale verificato
    Atlanta, Stati Uniti· Reclutamento
  • Assistenza Sanitaria Pediatrica di Atlanta
    Codice postale verificato
    Atlanta, Stati Uniti· Reclutamento
  • University of Michigan Health
    Codice postale verificato
    Ann Arbor, Stati Uniti· Reclutamento
  • University of Minnesota
    Codice postale verificato
    Minneapolis, Stati Uniti· Reclutamento
  • Science 37, Inc. (Virtual Clinical MetaSite)
    Codice postale verificato
    Morrisville, United States· Reclutamento
  • Hemophilia Center of Western PA
    Codice postale verificato
    Pittsburgh, United States· Reclutamento

Domande comuni

What is Von Willebrand Disease (VWD)?

VWD is a common bleeding disorder where your blood doesn't clot properly, which can lead to longer or heavier bleeding than usual.

What is VGA039?

VGA039 is a new medication being tested in this study to see if it can help prevent bleeding in people with VWD. It's given as an injection under the skin.

Cosa significa Fase 3?

Phase 3 is an important stage of research where a new medication is tested in a larger group of people to confirm its safety and how well it works before it can be considered for wider use.

Will I get the study medication right away?

No, there's an initial period of at least 24 weeks where you won't be taking the study medication, but doctors will gather information about your bleeding episodes.

Quanto durerà lo studio se partecipo?

The study involves an observation period of at least 24 weeks, followed by about 49 weeks of taking the study medication, so your total participation could be over a year.

Come saperne di più

Clinical Trials- Vega Therapeutics

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Study to Evaluate Subcutaneous (SC) VGA039 in Patients With …" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.